A Phase 2 interventional study of Remigromig and Aflibercept 2.0 mg in Neovascular Age-Related Macular Degeneration (NVAMD) and Branch Retinal Vein Occlusion (BRVO), sponsored by EyeBiotech Ltd.. Recruiting at 55 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by EyeBiotech Ltd. (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Retinal Vein Occlusion with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Retinal Vein Occlusion · United States.
Among the 106 studies in Retinal Vein Occlusion with a site in United States, this one is the 21st largest by planned enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 in phase 2, and was the 102nd registered.
289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.
Browse Retinal Vein Occlusion studies →6 of the 106 studies in Retinal Vein Occlusion with a site in United States are open now. Recruiting first, the newest first:
MediBeacon · Sites in United States
Ages 18+ · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–99 · Healthy volunteers
National Eye Institute (NEI) · Sites in United States
Ages 2–120 · Healthy volunteers
Harrow Inc · Sites in United States
Ages 18+
Retina Consultants of Delmarva · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 29 · Phase 3 25 · Phase 4 13
First in 2001; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.
Median enrollment 40 across the 90 interventional studies, 44 across the 16 observational. Of the 88 that completed or were terminated, 51 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 106 have an industry lead sponsor. The 10 most frequent:
This study is registered under EyeBiotech Ltd., one of the names counted as Merck & Co., Inc. Under that name alone:
EyeBiotech Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Merck & Co., Inc has 2 studies filed under Retinal Vein Occlusion — fewer than ten, so there is no comparison to draw.
4 of the studies in Retinal Vein Occlusion with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05476926Hoffmann-La RocheA Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products | 2026-11-30 |
| NCT04008121MediBeaconFeasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium | 2026-12 |
| NCT07891910Retina Consultants of DelmarvaIopidine to Decrease Intraocular Pressure Rise After Injections | 2026-12-01 |
| NCT04505618Johns Hopkins UniversityOptical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 106 studies in Retinal Vein Occlusion with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of remigromig via IVT or a high dose of remigromig via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion.
All participants in the study will receive a total of 3 injections of remigromig into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.
EYE-RES-104 is a randomized, dose-masked study of intravitreal remigromig in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
The study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of remigromig via IVT or a high dose of remigromig via IVT:
Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion.
All participants in the study will receive a total of 3 injections of remigromig into the study eye, spaced at 4 weeks apart. IR NVAMD participants in the combination therapy cohort will also receive an injection of aflibercept 2.0 mg in the study eye on Day 1.
All participants will be assessed for safety and efficacy at injection visits. Treatment naïve NVAMD participants and IR NVAMD participants in the monotherapy cohort will also return 2 weeks after each injection visit for safety and efficacy assessments. Depending on the cohort, participants will be evaluated every 2 weeks or every 4 weeks, including measurement of ETDRS BCVA, examination by slit-lamp biomicroscopy, fundoscopy, and SD-OCT. Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns. The Week 12 Visit will serve as the end of study visit for all participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Key General Inclusion Criteria
Key Neovascular Age-related Macular Degeneration (NVAMD)-specific Inclusion Criteria
Key Incomplete Responder (IR) NVAMD-specific Inclusion Criteria
Key Branch Retinal Vein Occlusion (BRVO)-specific Inclusion Criteria
Exclusion Criteria:
Key General Exclusion Criteria
Key NVAMD-specific Exclusion Criteria
Key BRVO-specific Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment Naïve NVAMD Cohort - Low Dose Remigromig (50 μL)
Drug: Remigromig
Treatment Naïve NVAMD Cohort - High Dose Remigromig (50 μL)
Drug: Remigromig
Incomplete Responder (IR) NVAMD Cohort - Low Dose Remigromig (50 μL)
Drug: Remigromig
Incomplete Responder (IR) NVAMD Cohort - High Dose Remigromig (50 μL)
Drug: Remigromig
Incomplete Responder (IR) NVAMD Cohort - Low Dose Remigromig (50 μL) in combination with Aflibercept 2.0 mg
Drug: Remigromig · Drug: Aflibercept 2.0 mg
Incomplete Responder (IR) NVAMD Cohort - High Dose Remigromig (50 μL) in combination with Aflibercept 2.0 mg
Drug: Remigromig · Drug: Aflibercept 2.0 mg
Treatment Naïve BRVO Cohort - Low Dose Remigromig (50 μL)
Drug: Remigromig
Treatment Naïve BRVO Cohort - High Dose Remigromig (50 μL)
Drug: Remigromig
Remigromig is a humanized antibody formulated for intravitreal administration
Also known as: Restoret, EYE103
Aflibercept 2.0 mg is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with Neovascular Age-Related Macular Degeneration (NVAMD). Aflibercept 2.0 mg is only administered to 2 cohorts of Incomplete Responders (IR) with NVAMD in combination with Low Dose or High Dose Remigromig.
Change from baseline in Best-Corrected Visual Acuity measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Change from baseline in Best-Corrected Visual Acuity measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Time frame: Week 12
Changes in retinal central subfield thickness (CST) based on spectral domain optical coherence tomography (SDOCT)
Changes in retinal central subfield thickness (CST) based on spectral domain optical coherence tomography (SDOCT)
Time frame: Duration of the study, through Week 12
Changes in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Changes in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Time frame: Duration of the study, through Week 12
Started Sep 2025 (actual). Primary completion is estimated for Jun 2028, 33 months after the start.
Of 14 phase 2 interventional studies under Retinal Vein Occlusion, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 29. This study's planned 33 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remigromig